埃森哲：COVID-19：引领医疗技术敏捷性和负责任的创新 -埃森哲（英文版）.pdf

1、NOWNEXTWhat to do Now, What to do NextCovid-19: MedTech industry April 2020 Leading with Leading with Agility Agility and Responsible and Responsible Innovation Innovation inin Response to Response to COVIDCOVID- -1919 NOWNEXTWhat to do Now, What to do NextCovid-19: 2 COVID-19 is a global crisis, ev

2、olving at unprecedented speed and scale. The MedTech industry is challenged as never before to re-imagine the design of mission critical devices and dramatically ramp-up production capacity. Front-line manufacturers of ventilators, PPE, beds, and other essential equipment need to provide their produ

3、cts to clinicians and patients within days. Simultaneously, the regulatory environment is adapting at breakneck pace, foregoing traditional processes to achieve speed-to-patient. Beyond COVID-19, patients and clinicians will likely have new expectations of how they interact with medical devices. As

4、we emerge from this global crisis, a new era for how MedTech serves the needs of clinicians and people will begin. Leading with Agility and Responsible Innovation in Response to Covid-19: MedTech Industry Anchor ResponseCopyright 2020 Accenture. All rights reserved. MedTech companies should tackle t

5、he challenges presented by COVID-19 with a mindset of responsible innovation, which is one focused on agility, affordability, and outcomes. Diagnostics are the frontline to stop COVID-19s spread. Lack of early detection contributed to rampant spread. Achieving widespread testing, testing efficiency,

6、 and ongoing monitoring is essential to restart economies, safely. COVID-19 is fueling unprecedented product innovation. Inventive engineers and clinicians are retrofitting or reimagining products in limited supply for new and expanded use. Centers for Medicare India relies on China for most of thei